STOCK TITAN

Seres Therapeutics, Inc. - MCRB STOCK NEWS

Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a pioneering clinical-stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products. These novel drugs aim to treat significant diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres is at the forefront of creating the first therapeutics that induce a shift towards health by enhancing the microbiome's biology.

The company operates primarily in the United States, leveraging its microbiome therapeutics platform to develop Ecobiotic™ microbiome therapeutics. These therapies are designed to restore health by repairing the function of a dysbiotic microbiome, particularly in the colon. Seres' lead product, SER-109, is developed to prevent the recurrence of Clostridium difficile infection (CDI), a severe infection of the colon. Additional product candidates include SER-262, SER-287, and SER-401.

Recently, Seres announced the sale of its VOWST assets to Nestlé Health Science under a non-binding memorandum of understanding. This transaction will provide Seres with capital infusions, including an upfront payment, and is expected to be completed in the next 90 days, subject to shareholder approval and other conditions. VOWST, the first FDA-approved oral microbiome therapy, prevents the recurrence of CDI in adults following antibacterial treatment for recurrent CDI.

Seres plans to use the capital from this transaction to retire its existing debt and strengthen its financial position. The company is also advancing SER-155, evaluated in a Phase 1b study in patients undergoing allogeneic hematopoietic stem cell transplantation. SER-155 has the potential to reduce gastrointestinal and related bloodstream infections, as well as acute graft-versus-host disease.

Seres Therapeutics continues to innovate in microbiome therapeutics, aiming to benefit multiple underserved patient groups, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The company's approach could protect millions of medically vulnerable patients from life-threatening infections while addressing the global public health issue of antimicrobial resistance (AMR).

Rhea-AI Summary
Seres Therapeutics, Inc. (MCRB) will host a conference call to discuss Q4 and full year 2023 results and provide a business update on March 5, 2024. Investors can access the call via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
conferences earnings
-
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) CEO to participate in a panel discussion at Cowen 44th Annual Health Care Conference. The event will be webcasted and archived for 21 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
conferences
-
Rhea-AI Summary
Seres Therapeutics, Inc. (MCRB) appoints Marella Thorell as CFO, succeeding David Arkowitz. Thorell brings extensive industry experience to drive financial strategy and advance product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
management
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) granted inducement equity grants to a new employee, consisting of stock options to purchase 45,000 shares of common stock and restricted stock units covering 22,500 shares of its common stock. The options have an exercise price of $1.21 per share and will vest over time, in accordance with the terms of the Inducement Plan adopted by the company's board of directors in December 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
none
-
Rhea-AI Summary
Seres Therapeutics, a leading microbiome therapeutics company (Nasdaq: MCRB), announced preliminary net sales of approximately $10.4 million for the fourth quarter of 2023. The company also reported significant adoption of VOWST, the first FDA approved orally administered microbiome therapeutic, with 2,833 patient enrollment forms received and 2,015 new patient starts. Additionally, SER-155 Phase 1b placebo-controlled Cohort 2 data readout is anticipated in the third quarter of 2024. Seres is set to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The company also received US FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections and reduce the incidence of severe acute graft-versus-host disease in immunocompromised patients undergoing allogeneic hematopoietic stem cell transplantation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
-
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will be available via audio webcast and replay, offering investors valuable insights into the company's future plans and strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced preliminary clinical data from a Phase 1b study of SER-155 for adult patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) at the 65th ASH Annual Meeting. The study aims to prevent enteric-derived infections, blood stream infections, and reduce the incidence of graft-versus-host disease (GvHD) by modulating immune responses in the gastrointestinal tract.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
-
Rhea-AI Summary
Seres Therapeutics, ticker symbol MCRB, will participate in the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023, at 3:30 p.m. ET. The audio webcast will be available on the company's website, with a replay accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
conferences
-
Rhea-AI Summary
Seres Therapeutics, Inc. reports Q3 2023 financial results, including VOWST net sales of $7.6 million. The company has received over 1,500 patient enrollment forms for VOWST since FDA approval. They also announced a strategic restructuring to focus on VOWST growth and reduce costs, resulting in a workforce reduction of 41% and anticipated annual cash savings of $75-$85 million in 2024. The restructuring is expected to support the company's operations into Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.28%
Tags
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) will release its third quarter 2023 financial results on November 2, 2023. A conference call with investors will be held at 8:00 a.m. ET. The webcast replay will be available on the Seres website for approximately 21 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags

FAQ

What is the current stock price of Seres Therapeutics (MCRB)?

The current stock price of Seres Therapeutics (MCRB) is $0.5497 as of November 15, 2024.

What is the market cap of Seres Therapeutics (MCRB)?

The market cap of Seres Therapeutics (MCRB) is approximately 94.8M.

What does Seres Therapeutics, Inc. do?

Seres Therapeutics, Inc. is a clinical-stage biotherapeutic company focused on developing Ecobiotic™ therapeutic products that target the human microbiome to treat diseases.

What is SER-109?

SER-109 is Seres Therapeutics' lead product designed to prevent the recurrence of Clostridium difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI.

What recent transaction did Seres Therapeutics announce?

Seres announced the sale of its VOWST assets to Nestlé Health Science, which includes transferring full product and intellectual property rights, pending shareholder approval and other conditions.

What is VOWST?

VOWST is the first FDA-approved oral microbiome therapy developed to prevent the recurrence of Clostridioides difficile infection (CDI) in adults post-antibacterial treatment for recurrent CDI.

What is the financial condition of Seres Therapeutics?

Seres plans to use the capital from its recent transaction with Nestlé Health Science to retire its existing debt and strengthen its financial position.

Who founded Seres Therapeutics?

Seres Therapeutics was founded by Flagship VentureLabs.

What other products are in Seres Therapeutics' pipeline?

In addition to SER-109, Seres is developing SER-262, SER-287, SER-401, and SER-155, each targeting different diseases related to the microbiome.

What partnerships does Seres Therapeutics have?

Seres has a significant partnership with Nestlé Health Science, which has been involved in the commercialization of VOWST.

What is the company's approach to treating diseases?

Seres' approach involves developing therapeutics that restore the function of the dysbiotic microbiome, aiming to treat a range of infectious, metabolic, and inflammatory diseases.

Where can I find more information about Seres Therapeutics?

For more information, visit Seres Therapeutics' official website at http://serestherapeutics.com/.

Seres Therapeutics, Inc.

Nasdaq:MCRB

MCRB Rankings

MCRB Stock Data

94.79M
170.20M
13.23%
41.2%
10.61%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE